

Salvatore Petta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2788809/publications.pdf>

Version: 2024-02-01

310
papers

17,049
citations

13865

67
h-index

17592

121
g-index

317
all docs

317
docs citations

317
times ranked

15341
citing authors

#	ARTICLE	IF	CITATIONS
1	AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1293-1302.e5.	4.4	22
2	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	12.1	113
3	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
4	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. <i>Transplantation</i> , 2022, 106, 462-478.	1.0	13
5	Is there an "ideal" diet for patients with NAFLD?. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13659.	3.4	28
6	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. <i>Digestive and Liver Disease</i> , 2022, 54, 1117-1121.	0.9	1
7	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
8	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	7.7	29
9	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
10	PSD3 downregulation confers protection against fatty liver disease. <i>Nature Metabolism</i> , 2022, 4, 60-75.	11.9	15
11	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	2.6	15
12	P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i236-i236.	1.3	1
13	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	3.7	18
14	LiFeStYle versus Ezetimibe plus lifestyle in patients with biopsy-proven Non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	2.6	3
15	Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. <i>JHEP Reports</i> , 2022, 4, 100444.	4.9	13
16	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.9	12
17	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.9	7
18	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 1032-1044.	4.3	6

#	ARTICLE	IF	CITATIONS
19	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	3.9	4
20	AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2022, 54, S17-S18.	0.9	0
21	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	4.9	31
22	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101925.	1.5	2
23	NAFLD/NASH. <i>Journal of Hepatology</i> , 2022, 77, 549-550.	3.7	10
24	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. <i>Nature Reviews Endocrinology</i> , 2022, 18, 638-650.	9.6	18
25	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021, 53, 1301-1307.	0.9	6
26	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 777-787.e17.	4.4	19
27	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	4.4	90
28	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	3.7	193
29	<i>PCSK9</i> rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021, 41, 321-332.	3.9	26
30	The Role of Transient Elastography in NAFLD. , 2021, , 61-74.		0
31	Rare and common ATG7 variants predispose to severe fatty liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, S26-S27.	0.9	0
32	New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: Evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM. <i>Digestive and Liver Disease</i> , 2021, 53, S16.	0.9	0
33	Increased serum ferritin levels predict long-term mortality in patients with NAFLD. <i>Digestive and Liver Disease</i> , 2021, 53, S28.	0.9	1
34	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.9	2
35	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 160, 1634-1646.e7.	1.3	82
36	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199.	2.0	11

#	ARTICLE	IF	CITATIONS
37	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , 2021, 8, 2004168.	11.2	10
38	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2389-2396.	2.8	6
39	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.9	13
40	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). <i>Digestive and Liver Disease</i> , 2021, 53, S49-S86.	0.9	7
41	Ultra-processed food is associated with features of metabolic syndrome and non-alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2635-2645.	3.9	46
42	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353.	2.6	40
43	Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. <i>Ultrasonography</i> , 2021, 40, 407-416.	2.3	11
44	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.	3.9	13
45	rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.	3.9	6
46	Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. <i>World Journal of Gastroenterology</i> , 2021, 27, 5112-5125.	3.3	5
47	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. <i>Journal of Hepatology</i> , 2021, 75, 659-689.	3.7	676
48	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1979-1981.	4.4	10
49	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
50	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
51	OC-06A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, S3-S4.	0.9	0
52	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 517-519.	4.4	12
53	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.	4.4	102
54	Development and Validation of Hepamet Fibrosis Scoring System – A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104

#	ARTICLE	IF	CITATIONS
55	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	7.3	209
56	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV monoinfected patients. <i>HIV Medicine</i> , 2020, 21, 96-108.	2.2	12
57	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020, 40, 530-538.	3.9	1
58	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	7.3	66
59	Outcomes of Liver Transplant for Adults With Wilson's Disease. <i>Liver Transplantation</i> , 2020, 26, 507-516.	2.4	12
60	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. <i>Digestive and Liver Disease</i> , 2020, 52, 359-367.	0.9	9
61	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817.	5.8	11
62	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
63	P162 Prevalence of nafld (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S219-S220.	1.3	2
64	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158765.	2.4	10
65	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020, 40, 2820-2827.	3.9	17
66	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
67	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2408-2416.	4.4	58
68	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2103-2110.	2.6	7
69	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.9	53
70	MAFLD vs NAFLD: Let the contest begin!. <i>Liver International</i> , 2020, 40, 2079-2081.	3.9	34
71	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020, 73, S13-S14.	3.7	4
72	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S20-S21.	3.7	0

#	ARTICLE	IF	CITATIONS
73	Europe's largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4). <i>Journal of Hepatology</i> , 2020, 73, S166-S167.	3.7	0
74	Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance. <i>Journal of Hepatology</i> , 2020, 73, S625-S626.	3.7	0
75	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. <i>Journal of Hepatology</i> , 2020, 73, S751-S752.	3.7	1
76	Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort. <i>Journal of Hepatology</i> , 2020, 73, S343.	3.7	0
77	Genetic variants in the MTHFR are not associated with fatty liver disease. <i>Liver International</i> , 2020, 40, 1934-1940.	3.9	5
78	Extrahepatic Manifestations of Chronic Viral C Hepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 347-360.	2.2	15
79	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1014-1022.	2.6	24
80	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. <i>Digestive and Liver Disease</i> , 2020, 52, e60.	0.9	0
81	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2020, 52, e8.	0.9	0
82	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with mild-moderate fibrosis, with or without glucose abnormalities: interim results of the EGG18 study. <i>Digestive and Liver Disease</i> , 2020, 52, e26-e27.	0.9	0
83	A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2020, 52, e40.	0.9	0
84	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020, 40, 1545-1555.	3.9	37
85	Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study. <i>Digestive and Liver Disease</i> , 2020, 52, e41-e42.	0.9	0
86	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e694-e701.	5.8	27
87	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort†. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
88	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020, 296, 40-47.	0.8	78
89	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.9	11
90	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 975-985.	0.4	3

#	ARTICLE	IF	CITATIONS
91	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. Current Pharmaceutical Design, 2020, 26, 1110-1118.	1.9	9
92	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 3928-3938.	1.9	3
93	The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries. , 2020, 58, .		0
94	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
95	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PLoS ONE, 2020, 15, e0243590.	2.5	3
96	Non-invasive Diagnostic Approach to NASH: Biological Markers. , 2020, , 235-256.		0
97	THU-335-FXR rs35724 C >G variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. Journal of Hepatology, 2019, 70, e307-e308.	3.7	0
98	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. International Journal of Environmental Research and Public Health, 2019, 16, 4334.	2.6	21
99	Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort. Digestive and Liver Disease, 2019, 51, e262-e263.	0.9	0
100	Point-of-care HCV RNA testing in the setting of DAA therapy: HCVâ€Fis (HEpatitis C Virus Fingerstick) Tj ETQq0,0,0 rgBT /6Overlock 1	3.9	0
101	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports, 2019, 1, 188-198.	4.9	86
102	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. Liver International, 2019, 39, 1742-1754.	3.9	51
103	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. Frontiers in Pharmacology, 2019, 10, 604.	3.5	16
104	PS-061-Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization and costs: Results from Italian administrative databases. Journal of Hepatology, 2019, 70, e37.	3.7	0
105	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. Digestive and Liver Disease, 2019, 51, e26.	0.9	3
106	Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization (HCRU) and costs: results from Italian administrative databases. Digestive and Liver Disease, 2019, 51, e27.	0.9	1
107	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	4.2	42
108	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	3.3	85

#	ARTICLE	IF	CITATIONS
109	Evaluating the association of serum ferritin and hepatic iron with disease severity in nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1325-1334.	3.9	48
110	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Digestive and Liver Disease</i> , 2019, 51, e4.	0.9	0
111	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	4.4	66
112	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	3.7	138
113	Effects of HCV eradication by DAA on oxidative stress parameters in patients with chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2019, 51, e59.	0.9	0
114	PNPLA3 rs738409 C>G variant predicts occurrence of liver-related events and death in non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2019, 51, e5-e6.	0.9	0
115	Characterizing compensated cirrhosis (CC) patients with potential etiology of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH): findings from large Italian administrative databases. <i>Digestive and Liver Disease</i> , 2019, 51, e49-e50.	0.9	1
116	Changes in 13C-aminopyrine breath test predict liver-related events and death in patients with HCV-related previous decompensated child A5 or child A6 to B cirrhosis who achieve SVR after DAA therapy. <i>Digestive and Liver Disease</i> , 2019, 51, e68.	0.9	0
117	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5613.	4.1	39
118	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
119	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019, 103, 22-27.	1.0	296
120	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	4.4	59
121	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019, 47, 141-168.	4.7	0
122	Liver and Statins: A Critical Appraisal of the Evidence. <i>Current Medicinal Chemistry</i> , 2019, 25, 5835-5846.	2.4	16
123	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24.	3.7	98
124	Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 31.	0.9	0
125	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. <i>Liver International</i> , 2018, 38, 2060-2068.	3.9	72
126	Role of the protein tyrosine kinase Mer (MerTK) in the cross-talk between macrophages and hepatic stellate cells. <i>Digestive and Liver Disease</i> , 2018, 50, 28-29.	0.9	0

#	ARTICLE	IF	CITATIONS
127	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. <i>Digestive and Liver Disease</i> , 2018, 50, 58.	0.9	0
128	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	1.3	291
129	Is global elimination of HCV realistic?. <i>Liver International</i> , 2018, 38, 40-46.	3.9	38
130	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. <i>Journal of Internal Medicine</i> , 2018, 283, 356-370.	6.0	256
131	Noninvasive prediction of esophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study. <i>Digestive and Liver Disease</i> , 2018, 50, 3-4.	0.9	0
132	Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 19.	0.9	0
133	Can we prevent and modify cardiometabolic disorders by controlling HCV infection?. <i>Gut</i> , 2018, 67, 403-404.	12.1	0
134	Usefulness of the index of NASH + ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018, 38, 715-723.	3.9	22
135	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	3.7	19
136	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018, 11, 121.	3.8	41
137	Expert Opinion on Managing Chronic HCV in Patients with Cardiovascular Disease. <i>Antiviral Therapy</i> , 2018, 23, 35-46.	1.0	8
138	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018, 13, 1139-1166.	2.0	2
139	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , 2018, 31, 685-712.	2.0	3
140	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> , 2018, 50, 1133-1152.	0.9	5
141	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018, 69, 1155-1163.	3.7	80
142	Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2018, 69, 1203-1204.	3.7	0
143	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. <i>Journal of Hepatology</i> , 2018, 68, S255-S256.	3.7	0
144	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 666-675.	4.3	38

#	ARTICLE	IF	CITATIONS
145	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	3.7	113
146	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	4.7	7
147	A <i>STAT4</i> variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 564-573.	3.7	17
148	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. <i>Cardiovascular Diabetology</i> , 2018, 17, 28.	6.8	43
149	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 740-749.	3.7	16
150	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	3.7	1,157
151	The membrane-bound O ⁶ -acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017, 65, 1840-1850.	7.3	74
152	Reply. <i>Hepatology</i> , 2017, 65, 2128-2128.	7.3	0
153	A meta-analysis of single HCV untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	3.9	70
154	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.9	254
155	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 65-71.	3.7	83
156	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017, 37, 1389-1396.	3.9	44
157	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.9	19
158	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2660-2669.	3.6	42
159	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	3.7	110
160	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1604-1611.e1.	4.4	146
161	Coffee and tea breaks for liver health. <i>Journal of Hepatology</i> , 2017, 67, 221-223.	3.7	10
162	Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, e17.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017, 49, e60.	0.9	5
164	High rate of misclassification of fibrosis stage using transient elastography thresholds to prioritize HCV patients for antiviral treatment. <i>Digestive and Liver Disease</i> , 2017, 49, e65-e66.	0.9	1
165	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017, 49, e59.	0.9	2
166	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 510-518.	3.7	169
167	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	2.8	43
168	Interferon lambda 4 rs368234815 T>G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 66, 1885-1893.	7.3	75
169	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
170	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <sc>NAFLD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
171	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695.	3.7	124
172	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
173	Hepatitis C virus and cardiovascular: A review. <i>Journal of Advanced Research</i> , 2017, 8, 161-168.	9.5	32
174	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <sc>HCV</sc> eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 160-168.	3.7	70
175	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.4	524
176	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	7.3	177
177	Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. <i>PLoS ONE</i> , 2017, 12, e0186136.	2.5	59
178	Evidence-Based Medicine and the Problem of Healthy Volunteers. <i>Annals of Hepatology</i> , 2017, 16, 832-834.	1.5	6
179	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
180	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	4.1	126

#	ARTICLE	IF	CITATIONS
181	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0163069.	2.5	63
182	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. Medicine (United States), 2016, 95, e3446.	1.0	44
183	Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver International, 2016, 36, 1765-1773.	3.9	17
184	Reply. Hepatology, 2016, 63, 1394-1394.	7.3	0
185	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	7.3	93
186	Reply. Hepatology, 2016, 64, 701-701.	7.3	0
187	rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. Liver International, 2016, 36, 198-204.	3.9	15
188	HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study. Digestive and Liver Disease, 2016, 48, e6-e7.	0.9	1
189	The cheating liver: imaging of focal steatosis and fatty sparing. Expert Review of Gastroenterology and Hepatology, 2016, 10, 671-678.	3.0	27
190	From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, 2016, 48, 995-1005.	0.9	13
191	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity, 2016, 17, 328-334.	4.1	12
192	Reply to "Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis". Journal of Hepatology, 2016, 64, 984-985.	3.7	1
193	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. Digestive and Liver Disease, 2016, 48, e7-e8.	0.9	3
194	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology, 2016, 63, 2032-2043.	7.3	239
195	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. Journal of Antimicrobial Chemotherapy, 2016, 71, 739-750.	3.0	13
196	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	3.7	106
197	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	1.3	506
198	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.9	56

#	ARTICLE	IF	CITATIONS
199	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016, 150, 145-155.e4.	1.3	201
200	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016, 16, 721-737.	1.3	13
201	Role of the receptor tyrosine kinase MER in the development of fibrosis in NAFLD. <i>Digestive and Liver Disease</i> , 2015, 47, e225.	0.9	0
202	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. <i>Digestive Diseases</i> , 2015, 33, 668-674.	1.9	10
203	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110.	7.3	183
204	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11088.	3.3	66
205	Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2015, 10, e0142210.	2.5	40
206	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-7.	1.4	22
207	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , 2015, 63, 705-712.	3.7	309
208	Epicardial fat in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 62, 1215.	3.7	3
209	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , 2015, 82, 48-52.	3.8	8
210	Current and future HCV therapy: do we still need other anti-HCV drugs?. <i>Liver International</i> , 2015, 35, 4-10.	3.9	33
211	Reply. <i>Hepatology</i> , 2015, 62, 660-660.	7.3	9
212	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015, 61, 506-514.	7.3	424
213	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 193-200.	3.6	28
214	The UCP2 -866G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. <i>Liver International</i> , 2015, 35, 1574-1580.	3.9	41
215	Chronic Intermittent Hypoxia is associated with Liver Damage and Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease. <i>Digestive and Liver Disease</i> , 2015, 47, e48-e49.	0.9	0
216	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 939-948.	3.7	18

#	ARTICLE	IF	CITATIONS
217	Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study. <i>Digestive and Liver Disease</i> , 2015, 47, e224-e225.	0.9	0
218	Response to Dr. Sertoglu and Colleagues. <i>Liver International</i> , 2015, 35, 285-286.	3.9	0
219	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1037-46.	2.4	52
220	Recurrence of hepatocellular carcinoma after liver transplantation: an update. <i>Future Oncology</i> , 2015, 11, 2923-2936.	2.4	40
221	Reply. <i>Hepatology</i> , 2015, 61, 1097-1097.	7.3	1
222	The presence of white matter lesions is associated with the histological severity of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2015, 47, e228.	0.9	0
223	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015, 62, 928-933.	3.7	162
224	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 1566-1573.	3.9	116
225	Cardiovascular diseases and HCV infection: a simple association or more?. <i>Gut</i> , 2014, 63, 369-375.	12.1	67
226	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". <i>Journal of Hepatology</i> , 2014, 60, 677-678.	3.7	1
227	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1.	4.4	13
228	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 523-529.	3.7	67
229	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014, 59, 1692-1705.	7.3	75
230	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 936-942.	0.9	17
231	Reply to: "Is industrial fructose just a marker of an unhealthy dietary pattern?". <i>Journal of Hepatology</i> , 2014, 61, 173-175.	3.7	0
232	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9
233	MERTK rs4374383 AA genotype is associated with a lower prevalence of severe hepatic steatosis in non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2014, 46, e2.	0.9	0
234	The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection. <i>Digestive and Liver Disease</i> , 2014, 46, e20.	0.9	0

#	ARTICLE	IF	CITATIONS
235	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e87523.	2.5	112
236	Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World Journal of Gastroenterology, 2014, 20, 16726.	3.3	2
237	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of Hepatology, 2013, 59, 1169-1176.	3.7	33
238	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 311-317.e1.	4.4	30
239	Reply. Hepatology, 2013, 57, 422-422.	7.3	0
240	Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients" Journal of Hepatology, 2013, 58, 403-404.	3.7	3
241	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2013, 45, e371.	0.9	0
242	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. Journal of Hepatology, 2013, 58, 771-777.	3.7	74
243	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis, 2013, 20, 174-182.	2.0	15
244	How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver International, 2013, 33, 23-29.	3.9	19
245	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. Journal of Hepatology, 2013, 59, 658-666.	3.7	41
246	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of Viral Hepatitis, 2013, 20, 486-493.	2.0	49
247	Insulin-Like Growth Factor-I, Inflammatory Proteins, and Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E304-E308.	3.6	69
248	Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance. Hepatitis Monthly, 2013, 13, e7176.	0.2	12
249	Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. BioMed Research International, 2013, 1-12.	1.9	26
250	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1046-1054.	7.3	89
251	NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis. PLoS ONE, 2013, 8, e68364.	2.5	26
252	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e74089.	2.5	59

#	ARTICLE	IF	CITATIONS
253	Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 5193-5218.	1.9	13
254	Chemoprevention for hepatocellular carcinoma: the role of statins. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 1-3.	1.5	0
255	Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 5193-218.	1.9	3
256	Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?. <i>Current Pharmaceutical Design</i> , 2013, 19, 5297-313.	1.9	11
257	Update on treatment strategies in patients with non-alcoholic fatty liver disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 5167-8.	1.9	0
258	Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients. <i>Antiviral Therapy</i> , 2012, 17, 111-118.	1.0	12
259	Vitamin D Levels and IL28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2012, 17, 823-831.	1.0	29
260	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of <sc>HCV</sc> infection. <i>Liver International</i> , 2012, 32, 1443-1450.	3.9	19
261	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012, 56, 1356-1362.	3.7	82
262	Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 1253-1260.e4.	1.3	604
263	Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. <i>Digestive and Liver Disease</i> , 2012, 44, 245-250.	0.9	11
264	Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: Spectators or actors?. <i>Digestive and Liver Disease</i> , 2012, 44, 359-360.	0.9	7
265	Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?. <i>BMC Infectious Diseases</i> , 2012, 12, S3.	2.9	9
266	Reproductive Status Is Associated with the Severity of Fibrosis in Women with Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e44624.	2.5	63
267	Serum $\hat{3}$ -glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases. <i>PLoS ONE</i> , 2012, 7, e51165.	2.5	29
268	Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1276.	1.8	8
269	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. <i>Hepatology</i> , 2012, 55, 1317-1323.	7.3	113
270	Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?. <i>Hepatology</i> , 2012, 55, 1309-1309.	7.3	2

#	ARTICLE	IF	CITATIONS
271	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 850-860.	7.3	97
272	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 238-247.	3.7	97
273	Visceral adiposity index and exercise in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 490-490.	3.7	1
274	Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 465-472.	2.0	12
275	Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 818-829.e2.	1.3	96
276	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011, 43, 404-410.	0.9	27
277	Comparison of Transient Elastography and Acoustic Radiation Force Impulse for Non-Invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 2112-2120.	0.4	177
278	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1350-1360.	3.7	126
279	Is liver stiffness measurement unreliable in obese patients? authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 255-256.	3.7	0
280	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 757-766.	3.7	125
281	Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1043-1044.	3.7	0
282	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. <i>Journal of Viral Hepatitis</i> , 2011, 18, e372-80.	2.0	20
283	Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. <i>Liver International</i> , 2011, 31, 36-44.	3.9	9
284	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011, 31, 507-515.	3.9	70
285	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 1158-1167.	7.3	371
286	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. <i>Hepatology</i> , 2010, 51, 1858-1858.	7.3	0
287	Reply:. <i>Hepatology</i> , 2010, 51, 2230-2230.	7.3	0
288	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010, 52, 1543-1552.	7.3	95

#	ARTICLE	IF	CITATIONS
289	Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association. <i>Current Pharmaceutical Design</i> , 2010, 16, 741-752.	1.9	61
290	658 HCV CONTRIBUTES TO INDUCE HEPATIC STEATOSIS DEREGULATING LIPID METABOLISM THROUGH LXR DEPENDING GENES MODULATION. <i>Journal of Hepatology</i> , 2010, 52, S256-S257.	3.7	0
291	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009, 49, 195-203.	7.3	65
292	Reply:. <i>Hepatology</i> , 2009, 49, 1394-1395.	7.3	0
293	Reply:. <i>Hepatology</i> , 2009, 49, 1776-1776.	7.3	0
294	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 603-613.	3.7	22
295	Serum BLYS/BAFF predicts the outcome of acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 397-405.	2.0	16
296	Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future. <i>Journal of Hepatology</i> , 2009, 50, 648-651.	3.7	31
297	Non-alcoholic fatty liver disease pathogenesis: The present and the future. <i>Digestive and Liver Disease</i> , 2009, 41, 615-625.	0.9	222
298	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 293-308.	4.4	66
299	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009, 14, 631-9.	1.0	7
300	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009, 14, 631-639.	1.0	22
301	Retinol-binding protein 4: A new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008, 48, 28-37.	7.3	55
302	Reply:. <i>Hepatology</i> , 2008, 48, 1725-1726.	7.3	1
303	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2008, 15, 523-530.	2.0	20
304	Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome. <i>Digestive and Liver Disease</i> , 2008, 40, A1-A2.	0.9	0
305	Retinol-binding protein 4 (RBP4): A new marker of G1 HCV-induced steatosis. <i>Digestive and Liver Disease</i> , 2008, 40, A29-A30.	0.9	0
306	Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 1136-1144.	0.4	170

#	ARTICLE	IF	CITATIONS
307	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1181-1191.	3.7	66
308	Anti-Tissue Transglutaminase Antibodies in Patients with Abnormal Liver Tests: Is It Always Coeliac Disease?. <i>American Journal of Gastroenterology</i> , 2005, 100, 2472-2477.	0.4	65
309	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
310	<i>NR1H4</i> rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0